Novavax Inc. (NVAX)
Shah Capital intends to vote against Novavax's board nominees, executive compensation
Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive compensation package at Novavax's upcoming annual meeting, renewing pressure for changes at the vaccine maker.
Novavax (NVAX) Stock Dips While Market Gains: Key Facts
In the closing of the recent trading day, Novavax (NVAX) stood at $8.02, denoting a -1.47% move from the preceding trading day.
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Novavax (NVAX) Falls More Steeply Than Broader Market: What Investors Need to Know
In the most recent trading session, Novavax (NVAX) closed at $8.95, indicating a -4.18% shift from the previous trading day.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Novavax, Inc. (NVAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Is Trending Stock Novavax, Inc. (NVAX) a Buy Now?
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof
Novavax (NVAX) has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties. NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high-margin cash flow, excluding potential $200M in milestones from Sanofi. With $857M in cash and receivables, NVAX is funded into 2028, but remains highly dependent on partner outcomes, especially Sanofi's COVID/influenza program.
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates
NVAX stock jumps 17% after Q4 swings to a surprise profit on strong licensing revenues and lower costs, with sales soaring 67% year over year.
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
